19 May 2025

AOTI, INC. (the "Company" or "Group" or "AOTI")

Presentation at AJ Bell and Shares Spotlight Event

AOTI, INC. (AIM: AOTI), a medical technology group focused on the durable healing of wounds and the prevention of amputations, will be presenting at the AJ Bell and Shares Spotlight Event in London, UK on Tuesday, 20 May 2025. The event will start at 17:15 BST and investors can register to attend here: https://ajbell.eventsair.com/shares-spotlight-events-london-20052025/200525/Site/Register.  

Dr. Mike Griffiths, Chief Executive Officer of AOTI, will be presenting an overview of the Company and will be available to take questions during the event.

ENDS

ABOUT AOTI, INC.

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO₂^®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO₂^® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO₂^® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. Also see www.aotinc.net